Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 5/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.37 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498704 | 0.91 | P2RX3 (0.45) | P2RX3PTGER1MRGPRX4 | |
| SCHEMBL6490213 | 0.86 | MRGPRX4 (0.40) | MRGPRX4PIK3C2BALOX5APDCTPP1 | |
| SCHEMBL6501198 | 0.85 | NR4A2 (0.48) | MRGPRX4ALOX5APDHODH | |
| SCHEMBL6493027 | 0.85 | MCL1 (0.43) | MRGPRX4PIK3C2BDHODH | |
| SCHEMBL6489174 | 0.84 | PIK3C2B (0.37) | P2RX3PIK3C2BALOX5APDCTPP1DHODH | |
| SCHEMBL6488551 | 0.83 | PIK3C2B (0.39) | PIK3C2BDHODH | |
| SCHEMBL6487037 | 0.83 | MRGPRX4 (0.46) | P2RX3MRGPRX4DCTPP1 | |
| SCHEMBL6489503 | 0.82 | CYSLTR1 (0.42) | MRGPRX4DCTPP1DHODH | |
| SCHEMBL6488028 | 0.81 | AGTR1 (0.40) | MRGPRX4DCTPP1DHODH | |
| SCHEMBL6492577 | 0.80 | DCTPP1 (0.41) | PIK3C2BPDE10AALOX5APDCTPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | P2RX3 2660/4885PTGER1 1980/4885MRGPRX4 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.